May 31, 2016
Treatment with a drug-coated balloon yielded favorable safety and efficacy outcomes among patients with infrapopliteal artery lesions in a single-center retrospective study.
The researchers reviewed data from 208 patients with symptomatic peripheral artery disease treated with a DCB (Lutonix, Bard/Lutonix) between May 2013 and October 2014 (mean age, 74.1 years; 138 men). The cohort included patients with critical limb ischemia (61.4% of patients) or severe claudication (38.6%) in 220 limbs. The majority of treated lesions (63.6%) were total occlusions, and 46.4% of patients had ischemia of category 5 at baseline.